Medtronic plc (MDT) faced a challenging week, with its stock price declining 6.1% to close at $73.81 on Friday, May 29. The drop marked the fourth consecutive session of losses for the medical device giant, and trading volume surged to more than double the 50-day average, indicating heightened investor activity.
Earnings Preview
The company is set to report its fiscal fourth-quarter and full-year 2026 results before the market opens on Wednesday, June 3. Options markets are pricing in a 4.1% move following the earnings release, according to Bloomberg data cited by Investing.com. Wall Street consensus estimates call for earnings per share of $1.54 on revenue of $9.62 billion, as reported by MarketBeat.
Medtronic's previous quarter showed revenue of $9.017 billion, up 8.7% on a reported basis and 6.0% organically. CEO Geoff Martha highlighted the strength of the portfolio, but analysts warn that growth may be slowing. Bernstein analyst Christian Moore noted that the reaffirmed full-year outlook implies a deceleration in the fourth quarter, while CFO Thierry Piéton indicated that additional tax costs could limit profit upside.
Market Context
The broader market showed mixed signals. While the S&P 500 edged up 0.22% on Friday, Medtronic's peers in the medtech sector also struggled. Abbott Laboratories fell 0.81%, Stryker lost 0.83%, and Boston Scientific dropped 1.63%. Boston Scientific continues to face headwinds from concerns about slowing growth in its Watchman device.
The holiday-shortened week, with the New York Stock Exchange closed on Monday for Memorial Day, added to the subdued trading environment. Investors are now focused on Medtronic's upcoming earnings and the company's forward guidance.
Strategic Acquisition
On May 20, Medtronic announced an agreement to acquire SPR Therapeutics, a private firm, for approximately $650 million in cash. The deal adds a 60-day peripheral nerve stimulation system to Medtronic's neuromodulation portfolio. The device delivers electrical pulses to nerves for pain management without requiring a permanent implant.
Domenico De Paolis, interim president of Medtronic's Neuromodulation division, stated that the acquisition will broaden access to neuromodulation therapies. The transaction is expected to close in the first half of fiscal 2027, pending regulatory approvals.
Outlook and Analyst Views
Despite the recent stock decline, analyst consensus remains relatively optimistic. Benzinga reports an average price target of $106.10 from 23 analysts, with UBS maintaining a neutral rating. However, with shares trading well below that target, the focus will likely shift to the company's outlook and ability to navigate headwinds such as tariffs, tax charges, and integration costs.
Wednesday's earnings report will be a key test for Medtronic, as investors assess whether the company can sustain its growth trajectory amid a challenging macroeconomic environment.
